Sengenics Announces Application Diversification Phase of its Immunome™ Protein Array Platform at Immunomics & Proteomics Symposium

Share on facebook
Share on google
Share on twitter
Share on linkedin

Sengenics today announced five new applications of its patented Immunome Protein Array platform at the Immunomics & Proteomics Symposium event being held in Singapore and Brunei from 25-29th July. The event is being co-hosted by Sengenics, Institute of Molecular and Cell Biology (IMCB), A*STAR, Singapore and Universiti Brunei Darussalam (UBD). Keynote speakers at the symposium include world renowned experts in the field of proteomics such as Professor Jonathan Blackburn, Sengenics Chief Scientific Advisor and Immunome Technology Inventor, Professor Hanno Langen, Global Head of Proteomics, Roche, Switzerland, and Professor Peter Nilsson, Head of Atlas Protein Array group, KTH, Sweden.


The ingenious surface technology of Immunome protein array makes it superior to those of its competitors, as it is able to identify biomarkers missed by other platforms and gives excellent signal-to-noise ratio. Every protein on the array is correctly folded and hence functional, making it ideal for a wide variety of proteomics applications, such as protein-protein and protein-DNA interaction profiling, on-array drug assays as well as monitoring adverse drug reactions in cancer immunotherapy clinical trials, said Professor Jonathan Blackburn.”


Recent publications using the Immunome protein array platform have highlighted its application for discovery of autoantibody biomarkers across many important diseases including melanoma, lupus, prostate cancer, Parkinson and malaria.


We are delighted and honoured to co-host this landmark event with Sengenics that brings together distinguished international experts in proteomics to share their knowledge and expertise with the local community. We hope everyone who attends will benefit from this once-in-a-lifetime opportunity to interact and discuss their own research ideas with such an eminent field of experts, said Dr Joyce Teo Siew Yean, Acting Vice Chancellor, UBD.


Sengenics collaborators have successfully filed co-patents based on novel biomarker findings using the Immunome platform. The aim is to roll out these findings into new clinical tests to enhance the accuracy of prognosis and diagnosis of diseases as well as applications relating to patient stratification and precision medicine in drug trials.


About Sengenics


Sengenics is a genomics and proteomics-based research and diagnostics company, with a range of patented technologies and products that are marketed to pharmaceutical companies, scientists and hospitals. Its flagship technology is the patented Immunome auto-antibody profiling platform which was spun out from research that was commercialised as a joint collaboration between the University of Oxford and the University of Cambridge in 1996. It also has additional patented and proprietary products for Human diseases that use the ThalaSURE and Genoverse brand names.



Related news link:

Leave a Reply

Sign up for our Newsletter

Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit


Resources to access our technology


Your technical questions - answered


One technology - endless possibilities

1996 – 2019 © Sengenics All rights reserved | Sengenics Corporation Pte Ltd. Registered in Singapore no. 201734100D | Sengenics UK Ltd. Registered in England and Wales No 11016361 

1996 – 2019 © Sengenics All rights reserved